A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper

Zozaya, Néboa; Villaseca Carmena, Javier; Abdalla, Fernando; Calleja Hernández, Miguel Ángel; Díez-Martín, José Luis; Estévez, J; García-Sanz, R; Martínez-López, Joaquín; Sierra, J; Vera, Ruth; Hidalgo, Álvaro.
Clin. transl. oncol. (Print) ; 24(6): 968-980, junio 2022. ilus
Artigo Inglês | IBECS (Espanha) | ID: ibc-203800

Documentos relacionados

  1. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
  2. Comparative analysis of cell therapy infusion workflows at clinical sites.
  3. [CAR-T cells, an innovative therapy].
  4. A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.
  5. Ocular adverse events following CAR-T cell therapy: A pharmacovigilance study and systematic review.
  6. CAR T cells are in it [CD]4 the long haul.
  7. High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.
  8. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
  9. Radiologic Imaging of CAR T-Cell Therapy: Looking under the Hood to Move Us Forward.
  10. CAR Traffic jam: who can use the fast lane?